For example, the bruton tyrosine kinase (BTK) inhibitors ibrutinib which elicts limited single-agent activity in DLBCLs but show a good therapeutic effect when combining with other immunotherapy agents, such as lenalidomide and rituximab.29 The promising therapy, chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. FDA in 2017, changed the treatment landscape of DLBCL. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.